Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study
Abstract Background The purpose of this study was to determine the prevalence of high disease activity as measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS) in ankylosing spondylitis (AS) patients who nonetheless have low Bath Ankylosing Spondylitis Disease Activity Index (BASD...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-02-01
|
| Series: | BMC Musculoskeletal Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12891-020-03941-8 |
| _version_ | 1818920351346720768 |
|---|---|
| author | Bora Nam Bon San Koo Tae-Han Lee Ji-Hui Shin Jin-Ju Kim Seunghun Lee Kyung Bin Joo Tae-Hwan Kim |
| author_facet | Bora Nam Bon San Koo Tae-Han Lee Ji-Hui Shin Jin-Ju Kim Seunghun Lee Kyung Bin Joo Tae-Hwan Kim |
| author_sort | Bora Nam |
| collection | DOAJ |
| description | Abstract Background The purpose of this study was to determine the prevalence of high disease activity as measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS) in ankylosing spondylitis (AS) patients who nonetheless have low Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores after anti-tumor necrosis factor (TNF) treatment. Its clinical impact on anti-TNF survival was also investigated. Methods We conducted a single-centre retrospective cohort study of AS patients having low BASDAI scores (< 4) and available ASDAS-C-reactive protein (CRP) data after 3 months of first-line anti-TNF treatment. Patients were grouped into high-ASDAS (≥ 2.1) and low-ASDAS (< 2.1) groups according to the ASDAS-CRP after 3 months of anti-TNF treatment. Their characteristics were compared. And survival analyses were carried out using Kaplan–Meier curves and log-rank test with the event being discontinuation of anti-TNF treatment due to lack/loss of efficacy. Results Among 116 AS patients with low BASDAI scores after 3 months of anti-TNF treatment, 38.8% were grouped into the high-ASDAS group. The high-ASDAS group tended to have greater disease activity after 9 months of treatment (BASDAI 2.9 ± 1.1 vs. 2.3 ± 1.4, p=0.007; ASDAS-CRP 1.8 ± 0.6 vs. 1.5 ± 0.7, p=0.079; proportion of high ASDAS-CRP 27.8% vs. 13.8%, p=0.094) and greater risk of discontinuing anti-TNF treatment due to lack/loss of efficacy than the low-ASDAS group (p=0.011). Conclusions A relatively high proportion of AS patients with low BASDAI scores had high ASDAS-CRP. These low-BASDAI/high-ASDAS-CRP patients also had a greater risk for discontinuation of anti-TNF treatment due to low/lack of efficacy than the low-ASDAS group. The use of the ASDAS-CRP alone or in addition to the BASDAI may improve the assessment of AS patients treated with anti-TNF agents. |
| first_indexed | 2024-12-20T01:20:22Z |
| format | Article |
| id | doaj.art-f2fd36aa99904b02adaefb4393d734df |
| institution | Directory Open Access Journal |
| issn | 1471-2474 |
| language | English |
| last_indexed | 2024-12-20T01:20:22Z |
| publishDate | 2021-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Musculoskeletal Disorders |
| spelling | doaj.art-f2fd36aa99904b02adaefb4393d734df2022-12-21T19:58:27ZengBMCBMC Musculoskeletal Disorders1471-24742021-02-012211810.1186/s12891-020-03941-8Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort studyBora Nam0Bon San Koo1Tae-Han Lee2Ji-Hui Shin3Jin-Ju Kim4Seunghun Lee5Kyung Bin Joo6Tae-Hwan Kim7Department of Rheumatology, Hanyang University Hospital for Rheumatic DiseasesDepartment of Rheumatology, Inje University Seoul Paik Hospital, Inje University College of MedicineDepartment of Rheumatology, Hanyang University Hospital for Rheumatic DiseasesDepartment of Rheumatology, Hanyang University Hospital for Rheumatic DiseasesMedical Affairs, AbbVie Ltd.Department of Radiology, Hanyang University Hospital for Rheumatic DiseasesDepartment of Radiology, Hanyang University Hospital for Rheumatic DiseasesDepartment of Rheumatology, Hanyang University Hospital for Rheumatic DiseasesAbstract Background The purpose of this study was to determine the prevalence of high disease activity as measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS) in ankylosing spondylitis (AS) patients who nonetheless have low Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores after anti-tumor necrosis factor (TNF) treatment. Its clinical impact on anti-TNF survival was also investigated. Methods We conducted a single-centre retrospective cohort study of AS patients having low BASDAI scores (< 4) and available ASDAS-C-reactive protein (CRP) data after 3 months of first-line anti-TNF treatment. Patients were grouped into high-ASDAS (≥ 2.1) and low-ASDAS (< 2.1) groups according to the ASDAS-CRP after 3 months of anti-TNF treatment. Their characteristics were compared. And survival analyses were carried out using Kaplan–Meier curves and log-rank test with the event being discontinuation of anti-TNF treatment due to lack/loss of efficacy. Results Among 116 AS patients with low BASDAI scores after 3 months of anti-TNF treatment, 38.8% were grouped into the high-ASDAS group. The high-ASDAS group tended to have greater disease activity after 9 months of treatment (BASDAI 2.9 ± 1.1 vs. 2.3 ± 1.4, p=0.007; ASDAS-CRP 1.8 ± 0.6 vs. 1.5 ± 0.7, p=0.079; proportion of high ASDAS-CRP 27.8% vs. 13.8%, p=0.094) and greater risk of discontinuing anti-TNF treatment due to lack/loss of efficacy than the low-ASDAS group (p=0.011). Conclusions A relatively high proportion of AS patients with low BASDAI scores had high ASDAS-CRP. These low-BASDAI/high-ASDAS-CRP patients also had a greater risk for discontinuation of anti-TNF treatment due to low/lack of efficacy than the low-ASDAS group. The use of the ASDAS-CRP alone or in addition to the BASDAI may improve the assessment of AS patients treated with anti-TNF agents.https://doi.org/10.1186/s12891-020-03941-8Ankylosing spondylitisDisease activityAnkylosing spondylitis disease activity score (ASDAS)Bath Ankylosing spondylitis disease activity index (BASDAI)Anti-tumor necrosis factor (anti-TNF) |
| spellingShingle | Bora Nam Bon San Koo Tae-Han Lee Ji-Hui Shin Jin-Ju Kim Seunghun Lee Kyung Bin Joo Tae-Hwan Kim Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study BMC Musculoskeletal Disorders Ankylosing spondylitis Disease activity Ankylosing spondylitis disease activity score (ASDAS) Bath Ankylosing spondylitis disease activity index (BASDAI) Anti-tumor necrosis factor (anti-TNF) |
| title | Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study |
| title_full | Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study |
| title_fullStr | Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study |
| title_full_unstemmed | Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study |
| title_short | Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study |
| title_sort | low basdai score alone is not a good predictor of anti tumor necrosis factor treatment efficacy in ankylosing spondylitis a retrospective cohort study |
| topic | Ankylosing spondylitis Disease activity Ankylosing spondylitis disease activity score (ASDAS) Bath Ankylosing spondylitis disease activity index (BASDAI) Anti-tumor necrosis factor (anti-TNF) |
| url | https://doi.org/10.1186/s12891-020-03941-8 |
| work_keys_str_mv | AT boranam lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy AT bonsankoo lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy AT taehanlee lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy AT jihuishin lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy AT jinjukim lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy AT seunghunlee lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy AT kyungbinjoo lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy AT taehwankim lowbasdaiscorealoneisnotagoodpredictorofantitumornecrosisfactortreatmentefficacyinankylosingspondylitisaretrospectivecohortstudy |